Our Beginning
May 1991
Myriad Genetics, Inc. is founded, making it one of the first genomics companies in history.
Myriad Genetics, Inc. is founded, making it one of the first genomics companies in history.
Myriad announces the discovery of the P16 gene that is associated with hereditary melanoma.
Myriad scientists publish in Science the discovery of the BRCA1 gene that is associated with hereditary breast and ovarian cancer.
Myriad becomes a public company and is traded on NASDAQ under the ticker: MYGN.
Myriad announces the discovery of the BRCA2 gene that is associated with hereditary breast and ovarian cancer.
Myriad launches BRACAnalysis®, the first full length gene sequencing test for a major, common disease, for the oncology market.
Myriad announces the discovery of major depression gene DEP1 in collaboration with Abbott Laboratories.
Myriad launches BRACAnalysis® for the women’s health preventative care market, significantly expanding access to genetic cancer testing.
Myriad launched Prolaris®, the first ever prognostic test to predict prostate cancer survival.
Myriad enters into three companion diagnostic collaborations for PARP inhibitors used in patients with ovarian cancer.
The one-millionth patient is tested with BRACAnalysis® test.
Myriad launches Myriad myRisk® Hereditary Cancer, a multi-gene panel test for eight hereditary cancers.
Myriad receives FDA approval for its BRACAnalysis CDx® test to identify ovarian cancer patients who may benefit from the PARP inhibitor Lynparza™ (olaparib).
Myriad acquires Assurex Health and the GeneSight® genetic test for several mental health conditions.
EndoPredict® test is launched in the United States, providing three separate results to optimize treatment for patients with breast cancer.
Myriad launches riskScore® test, providing eligible women with a comprehensive, personalized breast cancer risk assessment.
Myriad receives FDA approval for BRACAnalysis CDx® as a companion diagnostic for Lynparza™ in patients with metastatic breast cancer.
Myriad acquires Counsyl and enters the reproductive genetic testing market.
Myriad validates first ever polygenic score to predict breast cancer risk in women of Hispanic ancestry
Paul J. Diaz appointed President and Chief Executive Officer of Myriad Genetics.
Myriad Genetics joins forces with Intermountain Precision Genomics for a comprehensive offering of germline and somatic tumor testing services.